Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice
Authors
Keywords
-
Journal
XENOBIOTICA
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2020-04-20
DOI
10.1080/00498254.2020.1755909
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
- (2019) Hagop M. Kantarjian et al. CANCER
- Antibodies to watch in 2020
- (2019) Hélène Kaplon et al. mAbs
- A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
- (2018) Tomomi Nakayama Iwata et al. MOLECULAR CANCER THERAPEUTICS
- New FDA-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia
- (2018) Zach R Click et al. PHARMACOTHERAPY
- Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys
- (2018) Yoko Nagai et al. XENOBIOTICA
- DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance
- (2017) Naoki Takegawa et al. INTERNATIONAL JOURNAL OF CANCER
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
- (2017) Toshihiko Doi et al. LANCET ONCOLOGY
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer
- (2017) Paul Malik et al. PHARMACEUTICAL RESEARCH
- Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
- (2016) Takashi Nakada et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- (2016) Yusuke Ogitani et al. CANCER SCIENCE
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
- (2014) L. Amiri-Kordestani et al. CLINICAL CANCER RESEARCH
- Antibody-drug conjugates
- (2013) Alain Beck et al. mAbs
- U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
- (2012) R. A. de Claro et al. CLINICAL CANCER RESEARCH
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Irinotecan Pharmacogenetics in Japanese Cancer Patients: Roles of UGT1A1*6 and *28
- (2008) Kimie SAI et al. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started